Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 2/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
| ▸ | ABHD6 | Q9BV23 | 4/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
| ▸ | SLC6A15 | Q9H2J7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7381267 | 0.89 | ABHD6 (0.38) | PTGDR2ABHD6GPR119SMN1; SMN2P2RX4 | |
| SCHEMBL1983497 | 0.80 | MAPK1 (0.38) | SMN1; SMN2MEN1KMT2ATHRBCYP2D6 | |
| SCHEMBL3835092 | 0.79 | RAB9A (0.46) | PTGDR2MEN1GAAHTTKMT2A | |
| SCHEMBL304030 | 0.78 | LIPE (0.41) | GPR119SMN1; SMN2P2RX4CYP2D6BCHE | |
| SCHEMBL6306521 | 0.77 | TSHR (0.44) | SMN1; SMN2MEN1GAAHTTKMT2A | |
| SCHEMBL5412873 | 0.77 | ALDH1A1 (0.42) | PDE4BGPR119SMN1; SMN2MEN1GAA | |
| SCHEMBL2654623 | 0.77 | TSHR (0.40) | PDE4BGPR119SMN1; SMN2MEN1KMT2A | |
| SCHEMBL20215154 | 0.77 | PIK3CD (0.36) | SMN1; SMN2MEN1HTTKMT2A | |
| SCHEMBL13160 | 0.76 | ESR2 (0.48) | SMN1; SMN2MEN1KMT2ATHRB | |
| SCHEMBL12283406 | 0.75 | ALDH1A1 (0.45) | GPR119SMN1; SMN2MEN1GAAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3661923-B1 | N-HETEROCYCLIC COMPOUNDS AS OREXIN 2 AGONISTS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | TAKEDA PHARMACEUTICALS CO (JP) | 2024-05-15 | — | — | EP | disclosed |
| US-20230063805-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-03-02 | — | — | US | disclosed |
| US-11440883-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-09-13 | — | — | US | disclosed |
| CN-111051295-B | Heterocyclic compounds and their use | 武田药品工业株式会社 | 2022-09-02 | — | — | CN | disclosed |
| US-20200207715-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-07-02 | — | — | US | disclosed |
| US-20200207734-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-07-02 | — | — | US | disclosed |
| EP-3661923-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2020-06-10 | — | — | EP | disclosed |
| CN-111051295-A | Heterocyclic compounds and their use | 武田药品工业株式会社 | 2020-04-21 | — | — | CN | disclosed |
| US-10584097-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-03-10 | — | — | US | disclosed |
| US-20200017444-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-01-16 | — | — | US | disclosed |
| US-10428023-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-10-01 | — | — | US | disclosed |
| WO-2019027058-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-02-07 | — | — | WO | disclosed |
| US-20190040010-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190040010-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | HCRTR2, HCRTR1, CNR2 | PDE4B 1800/4885PTGDR2 416/4885ABHD6 3087/4885 |
| US-20200207734-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | HCRTR2, HCRTR1, CNR2 | PDE4B 1800/4885PTGDR2 416/4885ABHD6 3087/4885 |
| US-11440883-B2 | Heterocyclic compound and use thereof | HCRTR2, HCRTR1, CNR2 | PDE4B 1800/4885PTGDR2 416/4885ABHD6 3087/4885 |
| US-20230063805-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | HCRTR2, HCRTR1, CNR2 | PDE4B 1800/4885PTGDR2 416/4885ABHD6 3087/4885 |
| US-10428023-B2 | Heterocyclic compound and use thereof | HCRTR2, HCRTR1, CNR2 | PDE4B 1800/4885PTGDR2 416/4885ABHD6 3087/4885 |
| US-10584097-B2 | Heterocyclic compound and use thereof | HCRTR2, HCRTR1, CNR2 | PDE4B 1800/4885PTGDR2 416/4885ABHD6 3087/4885 |
| US-20200017444-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | HCRTR2, HCRTR1, CNR2 | PDE4B 1800/4885PTGDR2 416/4885ABHD6 3087/4885 |
| US-20200207715-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | HCRTR2, HCRTR1, CNR2 | PDE4B 1800/4885PTGDR2 416/4885ABHD6 3087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.